Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment
Completed · Phase 1 · NCT05661461
Conditions: Tumor, Solid, Tumor, Advanced Solid Tumor
At a glance
- Research payments reported, 2025
- $270,088
- U.S. investigators named
- 2
- Sites paid
- 3
- Planned or actual enrollment
- 15
About the trial
- Sponsor
- Aadi Bioscience, Inc.
- Tested
- nab-sirolimus (drug)
- Dates
- Started 2022-11-23; completion 2026-09-02
- Results posted
- Not yet
This is a phase 1, multi-center, open-label, dose-escalation study of nab-sirolimus in adult patients with locally advanced or metastatic solid tumors and moderate hepatic impairment or normal hepatic function.
From ClinicalTrials.gov, last updated 2026-10-28. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Aadi Bioscience, Inc. reported $270,088 in research payments for this study in 2025 (30 payments).
Products named: Fyarro
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Amita Patnaik, M.D. Medical Oncology · San Antonio, TX
- Justin A. Call, M.D. Medical Oncology · West Jordan, UT
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- South Texas Accelerated Research Therapeutics (start) $235,486
- South Texas Accelerated Research Therapeutics, LLC $33,832
- South Texas Accelerated Research Therapeutics Start $770
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.